Aktis Oncology priced an upsized US IPO that raised $318 million, signaling renewed investor appetite for radiopharmaceutical platforms. The Boston-based developer sold 17.65 million shares at $18 apiece and began trading on Nasdaq under ticker AKTS. Eli Lilly participated in the offering, buying a sizable block that underwrote demand. Aktis plans to use proceeds to advance its miniprotein radioconjugate pipeline, including Ac‑AKY‑1189 for Nectin‑4 and Ac‑AKY‑2519 for B7‑H3 tumors, and to fund phase 1b studies. The company noted a discovery partnership with Eli Lilly that could expand its target set. BioCentury and multiple market reports framed the IPO as the first biopharma test of 2026 public markets and a potential bellwether for more deals to follow.